Over the last 7 days, the United States market has dropped by 1.0%, yet it has seen a substantial rise of 38% over the past year, with earnings forecasted to grow by 15% annually. In this dynamic environment, identifying high growth tech stocks involves looking for companies that demonstrate robust innovation and adaptability to capitalize on these promising earnings projections.

Top 10 High Growth Tech Companies In The United States

Click here to see the full list of 247 stocks from our US High Growth Tech and AI Stocks screener.

Here we highlight a subset of our preferred stocks from the screener.

Turtle Beach

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Turtle Beach Corporation is an audio technology company with operations spanning North America, Europe, the Middle East, and the Asia Pacific, and it has a market cap of $356.77 million.

Operations: The company generates revenue primarily from its audio and video products, totaling $291.02 million. It operates across various regions including North America, Europe, the Middle East, and the Asia Pacific.

Turtle Beach Corporation, amid a challenging competitive landscape, is strategically expanding its market presence by launching new gaming accessories in international markets such as Canada and Latin America, evidenced by recent product accolades and positive reviews. Despite current unprofitability with a net loss reduction from $15.92 million to $7.52 million year-over-year for Q2 2024, the company's aggressive R&D investment aligns with its revenue growth forecast of 17.8% annually, outpacing the US market average of 8.9%. Moreover, Turtle Beach's commitment to innovation is underscored by its acquisition of Performance Designed Products LLC in 2024, enhancing its product offerings and potentially bolstering future profitability as projected over the next three years.

• Click to explore a detailed breakdown of our findings in Turtle Beach's health report.

• Learn about Turtle Beach's historical performance.

Precigen

Simply Wall St Growth Rating: ★★★★★☆

Overview: Precigen, Inc. is a discovery and clinical-stage biopharmaceutical company focused on developing gene and cell therapies for immuno-oncology, autoimmune disorders, and infectious diseases, with a market cap of approximately $269.97 million.

Operations: The company develops gene and cell therapies targeting immuno-oncology, autoimmune disorders, and infectious diseases using precision technology. Revenue is primarily derived from its Exemplar segment, contributing $4.31 million.

Precigen, despite recent financial setbacks with a net loss widening to $58.79 million in Q2 2024 from $20.32 million the previous year, remains a focal point for potential due to strategic shifts and innovation in gene therapy. The company's revenue forecasts are particularly promising, expecting an annual growth of 58.2%, significantly outpacing the US market average of 8.9%. This growth is underpinned by its focused R&D efforts which align with anticipated commercial launches, notably the PRGN-2012 AdenoVerse® gene therapy targeting recurrent respiratory papillomatosis set for a potential 2025 release following accelerated approval pathways. These strategic decisions are crucial as Precigen aims to transition from current unprofitability towards projected profitability within three years, reflecting an expected earnings growth of 64.1% per annum.

• Delve into the full analysis health report here for a deeper understanding of Precigen.

• Assess Precigen's past performance with our detailed historical performance reports.

2seventy bio

Simply Wall St Growth Rating: ★★★★★☆

Overview: 2seventy bio, Inc. is a cell and gene therapy company dedicated to the research, development, and commercialization of cancer treatments in the United States, with a market cap of $268.30 million.

Operations: The company generates revenue primarily from its biotechnology segment, amounting to $44.12 million. As a cell and gene therapy firm, it focuses on developing innovative cancer treatments within the U.S. market.

2seventy bio has demonstrated a notable turnaround, with Q2 2024 earnings revealing a net income of $24.88 million, a stark contrast to the net loss of $42.09 million in the same quarter last year. This resurgence is backed by robust revenue growth forecasts at an annual rate of 21.2%, significantly outstripping the US market's average of 8.9%. The company’s commitment to innovation is evident in its R&D strategy, with expenses aligning closely with these ambitious revenue targets, underscoring its potential within the biotech sector despite current unprofitability. Recent presentations at major industry events further highlight its active engagement with technological advancements and community within this high-stakes field.

• Get an in-depth perspective on 2seventy bio's performance by reading our health report here.

• Evaluate 2seventy bio's historical performance by accessing our past performance report.

Taking Advantage

• Discover the full array of 247 US High Growth Tech and AI Stocks right here.
• Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks.
• Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage.

Curious About Other Options?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include NasdaqGM:HEAR NasdaqGS:PGEN and NasdaqGS:TSVT.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com